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Local therapy for radiotherapy-associated angiosarcoma of the breast 
after organ-sparing treatment of primary breast cancer patients . A report 
of two cases and review of therapeutic options
Krystyna Serkies, Zuzanna Baczkowska-Waliszewska, Agata Kacprowska, Marcin Sinacki
Radiotherapy-associated angiosarcoma of the breast in breast cancer patients is a rare, poor-prognosis malignancy. 
Surgical resection with mastectomy is the standard local treatment for this disease. We present two cases of localized 
secondary angiosarcoma of the breast following breast-conserving therapy for early breast cancer, who underwent 
salvage mastectomy with R0 resection, followed by chemotherapy in one case. Both patients developed thoracic wall 
recurrence, and received palliative radio- and chemotherapy. In 23 months after being diagnosed with angiosarcoma, 
they died of uncontrolled local and distant disease. Our cases confirmed the high risk of local failure after salvage 
mastectomy due to radiotherapy-induced angiosarcoma. Based on literature, better local control might be achieved 
with more aggressive surgical approach with excision of all irradiated skin and soft tissue, and with re-irradiation. 
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Introduction
Radiotherapy is an essential part of breast-conserving 
therapy (BCT) for early breast cancer patients. It decreases 
loco-regional recurrence rates and improves overall survival 
(OS). Radiotherapy, however, has been associated with in-
creased second cancer risk at exposed sites, including sar-
comas. Five or more years after breast cancer radiotherapy, 
there is more than two-fold increase of second sarcomas 
(the estimated relative risk (RR) of 2.41). This risk was par-
ticularly evident for angiosarcoma (RR of 7.63 and of 13.7 
among +1-year and +5-year survivors, respectively) [1, 2]. 
Post-irradiation breast angiosarcoma (AS), the most frequent 
second type of sarcoma after primary breast cancer, has 
been increasingly reported, since currently most women 
with breast cancer have long-term survival [3].
ASs are rare malignant tumors that arise from endothelial 
cells, lining vascular channels. These tumors are character-
ized by rapid proliferation and extensive infiltrating growth. 
Angiosarcomas account for 0.0005–0.05% of all malignant 
breast neoplasms. Secondary angiosarcoma of the breast 
is found in women who have undergone breast-conserving 
surgery (BCS) and radiotherapy or chest wall radiotherapy. 
There are two types of this tumor: lymhedema-associated 
cutaneous angiosarcoma, first described in 1948 by Stewart 
and Treves, and post-irradiation angiosarcoma. The first case 
of radiation-associated angiosarcoma (RAAS) after BCS and 
radiotherapy was reported in 1981 [4]. The latency of RAAS 
is usually 3–12 years (median 7 years), but it can be up to 30 
years [1, 4, 5]. Extra chest wall metastases of RAAS including 
liver, lung, lymph nodes are rare, showing a spreading pattern 
different from that of primary angiosarcoma of the breast [6]. 
We present two cases of RAAS of the breast in BCT pa-
tients who underwent mastectomy and recent treatment 
options for such cases.
Artykuł w wersji pierwotnej:
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Table I . Characteristics and outcom
es of tw
o cases w
ith secondary angiosarcom
a of the left breast (located in another quadrant than prim
ary breast cancer localization) 
Case
Stage of breast
cancer
Pathology
of breast cancer 
Age at BCT
Prim
ary therapy
Latency 
(years)
Angiosarcom
a localization
Angiosarcom
a im
m
unoprofile
O
utcom
e/ survival 
(m
onths)
1.
cT2N
1
Invasive ductal 
carcinom
a
Grade II
ER, PR (+)
54
N
eoadjuvant CHT (6 cycles of 
doxorubicin and docetaxel), 
BCS (w
ith re-excision due to 
inadequate m
argin), 
W
BRT (w
ith supraclavicular region) 
50 Gy/25 fractions + boost 15 Gy
 a
6
Skin, parenchym
a
CD
31 (+), 
LCA (–), 
SM
A (–), 
CK5/6 (–),
CK AE1/AE3 (–), 
E-cadherin (–), Vim
entin (+), 
Podolanin (+/–)
D
 (23)
2.
cT1N
0
Invasive ductal 
carcinom
a
Grade II
ER, PR (+)
HER2 (–)
61
BCS, 
W
BRT 50 Gy/25 fractions + boost 15 
Gy
*, adjuvant HT 
(tam
oxifen for five years) 
9
Parenchym
a
CD
31 (+), CD
34 (+), 
CK AE1/AE3 (–), 
EM
A (–), 
Ki67 (+)/70%
D
 (23)
*The boost w
as given w
ith m
ulti-catheter pulsed-dose-rate brachytherapy (1 Gy per pulse repeated every hour) perform
ed after w
hole breast radiotherapy com
pletion or preceded breast irradiation as peri-operative procedure w
ith intra-operative tube 
placem
ent
BCT —
 breast-conserving therapy, HT —
 horm
one therapy, CHT —
 chem
otherapy, BCS —
 breast-conserving surgery, W
BRT —
 w
hole breast radiotherapy, D
 —
 death
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Case report 
Two cases of RAAS after BCT were identified among 320 
patients treated at the Medical University of Gdańsk, Poland, 
between 2000 and 2007 (Tab. I). In both, the primary sur-
gery consisted of upper-outer quadrantectomy and axillary 
lymph node dissection. Adjuvant radiotherapy consisted of 
whole breast radiotherapy (WBRT) with tangential fields and 
a boost dose to the tumor bed. The first patient received 
neoadjuvant chemotherapy, as well as irradiation to the 
supraclavicular region. Six years after BCT skin redness sim-
ilar to an orange peel (peau d’orange) overlaid the internal 
quadrants of the treated breast. Pathological examination 
of the skin specimen revealed no malignancy. Due to the 
appearance of new skin nodules with a few mm diameter, 
the repeated biopsy was done eight months later. The breast 
cancer local recurrence was diagnosed. At that moment, 
cancer dissemination was excluded by PET CT. The patient 
received docetaxel/cyclophosphamide chemotherapy and 
then underwent salvage mastectomy. The final diagno-
sis of AS epithelioides type was revealed. The slides from 
the previously resected skin were reviewed and showed 
former misdiagnosed sarcoma. Two months after mastec-
tomy RAAS in the form of red nodules progressed rapidly 
along both sides of the chest wall including the contralateral 
breast, with a metastasis in the right axillary lymph nodes. 
In addition to palliative thoracic radiotherapy (30 Gy in 10 
fractions) including re-irradiation of the left-side chest wall, 
she received chemotherapy with paclitaxel and liposomal 
doxorubicin but no response was obtained. In the case 2., 
RAAS was diagnosed after mastectomy performed due to 
breast tumor. Postoperatively the patient was treated with 4 
cycles of epidoxorubicine. Ten months later she experienced 
chest wall recurrence and developed bone and lung metas-
tases. In both cases salvage mastectomy was performed 
with free resection margins.
Discussion 
RAAS of the breast is a rare and difficult-to-treat disease. 
There are no established risk factors for RAAS. Apart from 
radiotherapy, partial mastectomies and lymph node dis-
sections were found to be independent risk factors for the 
development of breast RAAS [2]. The increasing use of newer 
techniques, i.e. intensity-modulated radiotherapy (IMRT) 
might be associated with a higher risk of mutagenesis. Due 
to the higher number of fields and monitor units IMRT has 
been shown to have greater out-of-beam doses including 
higher low-dose exposure of the normal structures. The 
addition of chemotherapy, including preoperative, an in-
creasingly applied strategy, might have also contributed to 
secondary malignancy. It is not clear whether AS is induced 
by radiation or persistent edema, or has a multifactorial 
origin. In most reported RAAS cases clinical lymphedema 
was not identified. Both our patients underwent axillary dis-
section and one received supraclavicular region irradiation. 
Hence, in spite of lack of clinical lymphedema, they might 
have had some minimal subclinical lymph stasis involving 
the breast. 
ASs grow in a multifocal pattern. Various changes in 
the irradiated breast have been described, with or without 
a palpable mass in the breast. Typically, patients present 
with a rapidly growing, painless breast mass within the 
radiation field. The overlying skin may have blue or pur-
ple discoloration. The appearance of such lesions on the 
irradiated breast may be confused with skin sequelae after 
radiotherapy, as was in our case leading to delayed diagno-
sis [7]. Moreover, epithelioides type, a rare subtype, can be 
more difficult to diagnose and must be distinguished from 
several diseases, including carcinoma and other sarcomas, 
as well as “atypical vascular lesions”, which may occur after 
radiotherapy. 
The overall prognosis for patients with RAAS is quite 
dismal with high rates of recurrences approaching 70–73% 
and poor median OS, ranging from 1.5–3 years with a 5-year 
OS of 15% [4]. The systematic review of 222 RAAS patients 
demonstrated OS of 43% at 5 years and the overall 5-year 
local recurrence free survival of 32% [8]. Tumor size and 
age were found to be independent predictors of adverse 
outcomes [4, 5, 8]. 
Surgical resection with salvage mastectomy is the stan-
dard treatment for RAAS. The patients with completely re-
sected tumors had improved median survival compared to 
patients with incomplete excision [9, 10]. Long-term survival 
in five of six patients with breast RAAS after BCT treated with 
resection of all irradiated skin and associated extra-tho-
racic soft tissue was reported [11]. The surgical treatment 
was planned using radiotherapy coordination tattoos and 
the patient’s radiation dose planning charts. Pre-operative 
MRI was used to determine the resection depth needed to 
achieve wide surgical margins in relation to the thoracic wall. 
The latter varied from including the deep fascia and superfi-
cial muscle tissue to include all extra-thoracic muscles and 
sometimes periosteal stripping of the ribs. Reconstructions 
were performed using pedicled m. latissimus dorsi or m. 
rectus abdominis flaps, and split thickness skin grafts. 
A high, mostly local, recurrence rate after surgery sug-
gests that adding re-irradiation to surgery improves the local 
control of RAAS [8]. There are reports of good results when 
hyperfractionated and accelerated radiotherapy (HART) 
are used, which reduces cell repopulation in these rapidly 
growing tumors [12, 13]. HART was given either before or 
after surgery [12]. With HART, patients received three radi-
ation treatments each day, with a minimum interfraction 
interval of four hours, five days a week, at 1 Gy per fraction, 
to the total doses of 45 Gy, 60 Gy, and 75 Gy for areas with 
a moderate and high risk for subclinical, and gross disease, 
respectively [13]. After the median follow-up of 7 years 
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five- and 10-year OS rates of 79% and 63%, respectively 
with HART, were achieved. 
The role of adjuvant chemotherapy is unclear. In the 
largest retrospective review on 95 patients with RAAS ad-
juvant chemotherapy reduced the risk of local recurrence 
[5]. Chemotherapy for RAAS consisted of combining anth-
racyclines, dacarbazine, and ifosfamide, as well as taxanes 
and gemcitabine. Two cases with locally relapsed RAAS 
who achieved complete remission following treatment with 
weekly paclitaxel were reported [14]. 
The roles of anti-angiogenic agents and tyrosine ki-
nase inhibitors that target c-KIT, including bevacizumab, 
pazopanib, sorafenib, and apatinib, are worthy of investi-
gation given the possible importance of the VEGF signaling 
pathway and the expression of CD117 in these tumors. The 
response rate to sorafenib of 33.3% (1 complete and 2 partial 
response) among 9 tumors [15], but no objective response 
in another series of 5 RAAS were reported [6].
Conclusion
RAAS of the breast is a rare, and late severe complica-
tion of BCT, which presents a potential challenge to the 
treating physician. Diagnosis can be challenging, as it may 
be misdiagnosed with both breast cancer recurrence and 
dermatologic findings. Salvage mastectomy, even with R0 
resection, for localized RAAS of the breast in BCT patients is 
associated with the high risk of local failure. Achieving better 
local control is possible by using more aggressive surgical 
approaches. Adding re-irradiation including HART to surgery 
might be beneficial for the local control of the RAAS. Ongo-
ing clinical trials using combination of VEGF inhibitors and 
chemotherapy may provide future avenues of treatment for 
this difficult-to-treat disease. In long-term BCT survivors the 
secondary AS should be kept in mind in the case of patients 
who developed changes of the irradiated breast. 
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